Weight Loss

GLP-1/GIP weight loss medications are finally affordable.

Simple, Straightforward Pricing

Semaglutide $126/month (7 week minimum purchace. 0.25 mg/week weeks 1-4; 0.5mg/week weeks 5-7)
Tirzepatide $159/month (8 week minimum purchace. 2.5 mg/week)

No consultation fee or any other hidden fees.

What is the difference between Tirzepatide and Semaglutide? They both help you lose weight, but Tirzepatide is a bit more effective. In a 72-week study, Semaglutide patients lost 13.7% of their body weight, while Tirzepatide patients lost 20.2% of their body weight.

GIP/GLP-1 receptor agonists give health benefits well beyond weight loss and glycemic control.

Cardiovascular Protection

A meta-analysis of 99,599 patients found that GLP-1s significantly reduce Major Adverse Cardiovascular Events, cardiovascular mortality, all-cause mortality, heart attack, stroke, and heart failure hospitalization, with benefits consistent across patients with or without diabetes, obesity, CKD, or heart failure.

Kidney Protection

In the FLOW trial Semaglutide reduced major kidney disease events by 24%, reduced cardiovascular death by 29%, and reduced all-cause death by 20% in patients with T2D and CKD.

Liver Disease (MASH/MASLD)

Tirzepatide demonstrated striking benefits in the SYNERGY-NASH trial: at 52 weeks, MASH resolution in 44–62% of tirzepatide-treated patients vs 10% with placebo

Obstructive Sleep Apnea

In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index by 20–24 events/hour more than placebo, with approximately 50% of patients achieving disease remission or non-symptomatic OSA.

Anti-Inflammatory Effects

A meta-analysis found that GLP-1s consistently reduce CRP, reduce oxidative stress markers (MDA), and increase adiponectin in patients with T2D. Tirzepatide specifically reduced IL-6 levels significantly.

Neuroprotection and Dementia Risk Reduction

Emerging evidence suggests GLP-1s may reduce dementia risk. A pooled post hoc analysis of three cardiovascular outcome trials showed a 53% reduction in dementia incidence with GLP-1s vs placebo.

Medical evaluation required. Prescription treatment, if appropriate, is provided only after consultation with a licensed medical provider. Results vary by individual.